Is Venetoclax a targeted drug?

Venetoclax/Venetoclax (Venetoclax) is a targeted drug designed to treat patients' diseases more precisely by specifically interfering with the survival mechanisms of cancer cells. The targeting of this drug is mainly reflected in its inhibition of BCL-2 (BCL-2) protein.

BCL-2protein is an anti-apoptotic protein. OverexpressionBCL-2 can make certain cancer cells resistant to apoptosis signals, thereby promoting the abnormal proliferation of these cancer cells. Venetoclax/Venetoclax breaks this resistance mechanism by specifically inhibiting the activity of BCL-2 protein, allowing cancer cells to respond normally to apoptosis signals, ultimately leading to the death of these cancer cells.

The design concept of targeted drugs is to achieve therapeutic effects by interfering with specific molecules or pathways in cancer cells while minimizing damage to normal cells. This differs from traditional methods of radiation and chemotherapy, which typically treat cancer by killing rapidly dividing cells, but they can also cause damage to normal cells, leading to a range of side effects.

Venetoclax/Venetoclax has been launched in China and has been included in medical insurance, and patients can purchase it domestically. Specifications: 100mg*14tablets and the price is around 5,000yuan. Please consult the local hospital pharmacy for specific prices. There are original drugs and generic drugs abroad. The Turkish version of Venetoclax/Venetoclaxoriginal drug on the market overseas, specification: 100mg*112 tablets, costs about 10,000 per box. Foreign generic drugs are relatively cheaper. For example, the generic drugs sold in Laos and Bangladesh are priced at about more than 4,000 yuan for 100mg*120 tablets. The ingredients of original drugs and generic drugs are basically the same.